17,191 Shares in Illumina, Inc. $ILMN Purchased by Empowered Funds LLC

Key Points

• Empowered Funds LLC acquired 17,191 Illumina shares during the second quarter, worth approximately $3.0 million. Institutional investors collectively own 89.42% of the company, with major new positions also reported by BlackRock, Primecap Management and others.
• Illumina reported quarterly earnings of $1.31 per share, exceeding estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. The company guided to fiscal 2026 earnings of $5.30–$5.40 per share.
• The stock opened at $213.25, above its $188.40 analyst consensus price target; analyst sentiment remains mixed, resulting in an overall “Hold” rating. Insiders have sold approximately $379.5 million of shares over the past 90 days.

Empowered Funds LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,191 shares of the life sciences company's stock, valued at approximately $3,023,000.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Illumina in the 2nd quarter worth approximately $3,374,423,000. Primecap Management Co. CA purchased a new stake in Illumina during the 2nd quarter valued at $617,981,000. Jupiter Topco LLC purchased a new stake in Illumina during the 2nd quarter valued at $358,652,000. WCM Investment Management LLC lifted its position in Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock worth $715,579,000 after buying an additional 1,851,848 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in Illumina in the second quarter worth $293,846,000. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

Shares of Illumina stock opened at $213.25 on Thursday. The stock's fifty day moving average is $196.70 and its two-hundred day moving average is $157.87. The company has a market capitalization of $32.20 billion, a PE ratio of 39.79, a price-to-earnings-growth ratio of 2.93 and a beta of 1.46. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $231.81.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 earnings per share. The business's revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Transactions at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the firm's stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the transaction, the senior vice president owned 21,259 shares of the company's stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of Illumina stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company's stock, valued at $2,685,684.96. The trade was a 6.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,799,688 shares of company stock worth $379,517,231. Insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ILMN. Wall Street Zen upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research report on Saturday, August 1st. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a "hold" rating in a report on Wednesday, August 5th. Barclays lifted their price target on shares of Illumina from $145.00 to $160.00 and gave the stock an "underweight" rating in a research note on Friday, July 31st. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Zacks Research raised shares of Illumina from a "hold" rating to a "strong-buy" rating in a research report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $188.40.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.